Sørensen, Anne Mette Skov http://orcid.org/0000-0001-7399-8228
Wesselhöeft, Rikke
Andersen, Jacob Harbo
Reutfors, Johan
Cesta, Carolyn E.
Furu, Kari
Hartz, Ingeborg
Rasmussen, Lotte
Article History
Received: 16 February 2022
Accepted: 20 June 2022
First Online: 13 July 2022
Change Date: 25 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00787-022-02100-9
Declarations
:
: Johan Reutfors and Carolyn Cesta are employed at the Centre for Pharmacoepidemiology, Karolinska Institutet, which receives grants from several entities (contract research organizations, regulatory authorities, and pharmaceutical companies including AbbVie, AstraZeneca, Bayer, Janssen, Pfizer, Servier, and Takeda) for performance of drug safety and drug utilization studies, with no relation to the work reported in this paper. The other authors did not receive support from any organization for the submitted work.
: The aggregated data used for this study are publicly accessible in the three countries and, therefore, approval from ethical committees or data protection agencies was not needed.